戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 atients aged 60 years or older with isolated systolic hypertension.
2 e-associated vascular stiffness and isolated systolic hypertension.
3 olic BP in postmenopausal women with stage 1 systolic hypertension.
4 lay an active role in the pathophysiology of systolic hypertension.
5 adults (aged 60 years or more) with isolated systolic hypertension.
6 y function among older persons with isolated systolic hypertension.
7 patrilat 80 mg daily (n=80) in patients with systolic hypertension.
8 olled trials has been beneficial in isolated systolic hypertension.
9 ch occurs with aging, diabetes, and isolated systolic hypertension.
10 d extend the findings to borderline isolated systolic hypertension.
11 portant in older men and women with isolated systolic hypertension.
12 , 95% CI: 1.10, 1.26), but not with isolated systolic hypertension.
13 , though they require follow-up for incident systolic hypertension.
14 o 1.87) and 1.68 (1.58 to 1.78) for isolated systolic hypertension, 1.59 (1.43 to 1.76) and 1.45 (1.2
15 th diabetes, -8.6 +/- 18.7 mm Hg in isolated systolic hypertension, -10.1 +/- 20.3 mm Hg in chronic k
16  four components best describe the data: (1) systolic hypertension, (2) general hypertension, (3) res
17  Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that ini
18  Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial, we aimed to in
19  COMbination Therapy in Patients Living With Systolic Hypertension [ACCOMPLISH]; NCT00170950).
20 d other covariates and by a higher effect of systolic hypertension among persons in the lowest quarti
21 h age and contributes to the pathogenesis of systolic hypertension and cardiovascular disease in the
22                        Treatment of isolated systolic hypertension and combined systolic and diastoli
23 olol for treatment of patients with isolated systolic hypertension and ECG-LVH.
24                                  TG mice had systolic hypertension and hypertrophy similar to those s
25 ndothelial cells developed-upon aging-severe systolic hypertension and impaired endothelium-dependent
26 ean arterial pressure variably contribute to systolic hypertension and increased cardiovascular risk.
27 (HF-nlEF) is common in aged individuals with systolic hypertension and is frequently ascribed to dias
28 e in aortic stiffness likely further worsens systolic hypertension and its attendant end-organ damage
29 significant and positive association between systolic hypertension and liver expression levels of glu
30 nts study in patients >=75 years of age with systolic hypertension and magnetic resonance imaging evi
31      Most importantly, we review the risk of systolic hypertension and pulse pressure hypertension in
32 coronary artery calcium (CAC), (ii) incident systolic hypertension, and (iii) CVD events.
33 essure (SBP), the prevalence of uncontrolled systolic hypertension, and cardiovascular mortality attr
34 aortic hypoplasia, calcific atherosclerosis, systolic hypertension, and premature cataract.
35  Hypertension as well as borderline isolated systolic hypertension are associated with elevated risks
36  factors, such as hypercholesterolaemia and (systolic) hypertension, are shared among atherosclerotic
37  effective in elderly patients with isolated systolic hypertension, attention has been focused on the
38 ve individuals and individuals with isolated systolic hypertension but not in individuals with diasto
39  Heart failure is often preceded by isolated systolic hypertension, but the effectiveness of antihype
40 the time of scanning are small, but isolated systolic hypertension could cause increases in spurious
41                Better clinical management of systolic hypertension depends on greater insight into th
42 on cardiovascular health, including isolated systolic hypertension, excessive penetration of pulsatil
43 essure that separates patients with isolated systolic hypertension from those with essential hyperten
44  a female donor heart, doubling the cases of systolic hypertension (from 6 to 13/14; 46% to 93%, P =
45 at is characterized by the early presence of systolic hypertension, glomerular hypertension, progress
46 as found in 48 (44%) patients (18 male), and systolic hypertension (>140 mmHg) was found in 69 (63%)
47   In survival models, a continuous burden of systolic hypertension (>=140 mm Hg; hazard ratio per uni
48               Studies of the pathogenesis of systolic hypertension have lagged.
49 ssociation between homocysteine and isolated systolic hypertension in older adults was evaluated usin
50  the United States consist of isolated, mild systolic hypertension in older adults, most of whom have
51 m (SHEP) demonstrated that treating isolated systolic hypertension in older patients decreased incide
52 eine may be related to the cause of isolated systolic hypertension in some individuals.
53 TICIPANTS: The Optimising Treatment for Mild Systolic Hypertension in the Elderly (OPTIMISE) study wa
54 r adults, the authors analyzed data from the Systolic Hypertension in the Elderly Program (1984-1990)
55                                          The Systolic Hypertension in the Elderly Program (SHEP) demo
56                                       In the Systolic Hypertension in the Elderly Program (SHEP) tria
57 and women enrolled in the placebo arm of the Systolic Hypertension in the Elderly Program (SHEP).
58                                          The Systolic Hypertension in the Elderly Program recruited 4
59                                          The Systolic Hypertension in the Elderly Program recruited 4
60 es confirm the benefits of treating isolated systolic hypertension in the elderly.
61 p could ultimately help reduce the burden of systolic hypertension in underserved populations and thu
62 tic cardiovascular disease, type 2 diabetes, systolic hypertension, insulin resistance, and nonalcoho
63 n contrast to the wealth of data on isolated systolic hypertension involving the systemic circulation
64                                              Systolic hypertension is common in patients hospitalized
65                                     Managing systolic hypertension is especially difficult in underse
66                                     Isolated systolic hypertension is the dominant variety.
67                                     Isolated systolic hypertension is the predominant form of hyperte
68 lence of arterial hypertension, particularly systolic hypertension, is constantly rising worldwide.
69 lic/diastolic hypertension, whereas isolated systolic hypertension (ISH) is common among persons over
70 problem among elderly patients with isolated systolic hypertension (ISH), but the effect of treatment
71                                     Isolated systolic hypertension (ISH), defined as systolic blood p
72  of stroke in elderly patients with isolated systolic hypertension (ISH).
73  Model-TV demonstrated that mild to moderate systolic hypertension may be relatively well tolerated.
74 edictors of type II outcomes were older age, systolic hypertension on admission, pulmonary disease, a
75 teine remained significantly associated with systolic hypertension (P=.019).
76 efinite hypertension and borderline isolated systolic hypertension predict subsequent cardiovascular
77 ocardial infarction, and borderline isolated systolic hypertension predicts a possible but more modes
78 specially in older patients in whom isolated systolic hypertension predominates, controlling 70% to <
79       METHODS AND COX-1>COX-2 mice developed systolic hypertension relative to wild types (WTs) on a
80 o developments of pulmonary hypertension, RV systolic hypertension, RV dilation, RV dysfunction, and
81 (SBP >or=140 and DBP >or=90 mm Hg), isolated systolic hypertension (SBP >or=140 and DBP <90 mm Hg), i
82  Blood Pressure emphasizes the importance of systolic hypertension (SH), defined as systolic blood pr
83                       Patients with isolated systolic hypertension should be treated, but marked dias
84                    Low-grade proteinuria and systolic hypertension (SHT) are risk factors for allogra
85               In older persons with isolated systolic hypertension, stepped-care treatment based on l
86                          The odds ratios for systolic hypertension suggest a similar but weaker assoc
87  assessed in 128 subjects with uncomplicated systolic hypertension (supine systolic pressure > or =14
88                    This review describes the systolic hypertension syndrome as a complex set of hemod
89 up; they were also observed in patients with systolic hypertension (systolic blood pressure > or = 14
90 arly, while IDH was associated with incident systolic hypertension, there was no statistically signif
91  COMbination Therapy in Patients Living With Systolic Hypertension) trial compared the outcomes effec
92 te Cox regression modeling demonstrated that systolic hypertension was a significant independent pred
93                                     Isolated systolic hypertension was associated with increased risk
94                             Mild to moderate systolic hypertension was associated with only modest in
95                          Borderline isolated systolic hypertension was associated with significantly
96                               Elevated PP in systolic hypertension was independent of MAP and was att
97         Hypertension and borderline isolated systolic hypertension were associated with significantly
98  in salt, the EP2-/- mice developed profound systolic hypertension, whereas wild-type mice showed no
99 rosclerotic renal-artery stenosis and either systolic hypertension while taking two or more antihyper
100     In the SHEP trial, treatment of isolated systolic hypertension with chlorthalidone stepped-care t
101 t PP plus other basic information can detect systolic hypertension with ROC AUC of 0.9.
102 ged >/=60 years (older) have mainly isolated systolic hypertension, with major trials attaining systo
103  age <65 years, with versus without isolated systolic hypertension, with versus without atrial fibril

 
Page Top